RxDoctor Payments Data

Thomas Chi, MD

Urology · Birmingham, ALNPI 1245360320

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $338,436 of the $463,287 with a category attached, or 73.1%. Johnson & Johnson accounts for 61.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $228,742 and has fallen 82.6% since, to $39,881 in 2025. Among urology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$463,287in general payments, 2019–2025

Across 226 payments — averaging $2049.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$286K
  • Boston Scientific$97K
  • Cook Incorporated$39K
  • C. R. Bard, Inc. & Subsidiaries$12K
  • Calyxo, Inc.$10K
  • Alnylam Pharmaceuticals Inc.$9K
  • plus $10K from 11 others
$186,576in research payments, 2019–2025

Across 29 payments — averaging $6433.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$101K
  • Alnylam Pharmaceuticals Inc.$64K
  • Calyxo, Inc.$22K

What the payments were for

  • Consulting fees$97,31421%
  • Speaking & faculty fees$338,43673%
  • Travel & lodging$19,8624%
  • Food & beverage$6,9271%
  • Education$5000%
  • Entertainment$2480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$463,287 in reported general payments places this provider in the 95th percentile of 179 urology providers in Alabama.

See all urology providers in Alabama

Medicare billing

Part B allowed, 2024
$156,860
Medicare patients
393
Services billed
951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron62$46,605
GemtesaVibegron21$21,983
Tadalafil51$10,667
Trospium Chloride ErTrospium Chloride17$4,532
Potassium Citrate ErPotassium Citrate28$4,327
Tamsulosin Hcl117$1,508
Oxybutynin Chloride ErOxybutynin Chloride35$954
Alfuzosin Hcl ErAlfuzosin Hcl45$889
Silodosin13$805
Trospium Chloride15$656
Finasteride62$554
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav20$219
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim22$69
NitrofurantoinNitrofurantoin Macrocrystal12$17

Paid to pharmacies, not to this prescriber.

Other urology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →